Jade Biosciences, Inc. (JBIO)
| Market Cap | 1.30B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -100.14M |
| Shares Out | 49.32M |
| EPS (ttm) | -3.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 555,964 |
| Open | 27.28 |
| Previous Close | 26.85 |
| Day's Range | 25.50 - 27.45 |
| 52-Week Range | 6.57 - 28.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 31.20 (+17.94%) |
| Earnings Date | May 14, 2026 |
About JBIO
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for JBIO stock is "Strong Buy." The 12-month stock price target is $31.2, which is an increase of 17.94% from the latest price.
News
Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO and VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on dev...
Jade Biosciences Appoints Edward R. Conner, M.D.
SAN FRANCISCO and VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on dev...
Jade Biosciences Transcript: Leerink Global Healthcare Conference 2026
The company is advancing a best-in-class anti-APRIL antibody for IgA nephropathy, aiming for less frequent dosing and superior efficacy, with phase I data expected soon and rapid progression to phase II. Market research highlights strong demand for extended dosing intervals, and the pipeline includes additional autoimmune programs and expansion opportunities.
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
SAN FRANCISCO and VANCOUVER, British Columbia, March 06, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in...
Jade Biosciences Transcript: TD Cowen 46th Annual Health Care Conference
Three antibody programs are advancing, with JADE101 targeting IgA nephropathy and phase I data expected 1H 2024. The company is focused on best-in-class efficacy, convenient dosing, and robust biomarker-driven development, with a strong cash position and potential for accelerated regulatory pathways.
Jade Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The presentation highlighted a robust pipeline targeting autoimmune diseases, with JADE101 poised for key data in IgA nephropathy and JADE201 advancing into clinical trials for broader autoimmune indications. Strong financials support rapid development and multiple upcoming milestones.
Jade Biosciences to Participate in Upcoming Conferences
SAN FRANCISCO and VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies ...
Jade Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company is advancing a pipeline of best-in-class autoimmune therapeutics, led by JADE101 for IgA nephropathy, aiming for superior efficacy and convenience. With strong financial backing and experienced leadership, it targets large, expanding markets and plans rapid clinical progression.
Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference
JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin mi...
Jade Biosciences Announces $45 Million Private Placement
SAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on dev...
Jade Biosciences Transcript: Jefferies London Healthcare Conference 2025
The team presented progress on a robust autoimmune pipeline, highlighting anti-APRIL as a potential foundational therapy for IgAN with strong early data and a favorable safety profile. Regulatory and market trends support continued efficient development and expansion into new indications.
Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Presented favorable preclinical safety data for JADE101 and a translational analysis of APRIL mediated biomarker responses at the American Society of Nephrology Kidney Week 2025, reinforcing its poten...
Jade Biosciences Transcript: TD Cowen Immunology and Inflammation Summit
A novel anti-APRIL antibody is advancing for IgA nephropathy, aiming for best-in-class potency, extended dosing, and a favorable safety profile, with phase I data expected next year. Pipeline expansion includes a long-acting anti-BAFF-R antibody for autoimmune diseases.
Jade Biosciences Transcript: Stifel 2025 Healthcare Conference
The company is advancing a pipeline of antibody therapies for autoimmune diseases, with lead asset JADE101 targeting IgA nephropathy and aiming for best-in-class efficacy and convenience. Strong financials support rapid clinical development, with key data readouts expected in 2025.
Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025
SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on dev...
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025
Presentations to highlight JADE101's preclinical safety profile and translational framework guiding its clinical development in IgA nephropathy JADE101 is an investigational, potentially best-in-class...
Jade Biosciences Transcript: Investor Update
Secured $135M in financing to fund operations into 2028 and advance JADE101 and JADE201, with the latter set for a first-in-human RA study in 2026. JADE201's dual mechanism and half-life extension aim for best-in-class B-cell depletion and broad autoimmune potential.
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases
JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell d...
Jade Biosciences Announces $135 Million Private Placement
SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on dev...
Jade Biosciences Transcript: Stifel Virtual Immunology and Inflammation Forum
The company is advancing Jade 101, a highly potent anti-APRIL antibody for IGAN, with phase one data expected in the first half of next year and plans for efficient pivotal development. New KDIGO guidelines and strong clinical data position anti-APRILs as future frontline therapy. The pipeline includes additional autoimmune targets, and funding is secured through 2027.
Jade Biosciences Transcript: Cantor Global Healthcare Conference 2025
Jade Biosciences, led by experienced biotech executives, is advancing a pipeline of autoimmune therapeutics, highlighted by JADE101, a next-generation anti-APRIL antibody for IgAN. With strong financing and a data-driven approach, the company targets best-in-class efficacy and dosing, aiming for key clinical milestones in the next year.
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy
Selective APRIL inhibition has shown disease-modifying potential in IgAN patient clinical trials JADE101 has shown ultra-high binding affinity and a differentiated pharmacokinetic and pharmacodynamic ...
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Presented preclinical data for JADE101 at the 62nd European Renal Association Congress, highlighting its potential as a best-in-class anti-APRIL monoclonal antibody for IgA nephropathy Phase 1 healthy...
Jade Biosciences Transcript: H.C. Wainwright 4th Annual Kidney Virtual Conference
Jade is advancing a pipeline of autoimmune therapies, led by Jade101 for IgA nephropathy, with clinical entry planned for late 2024 and a key readout in H1 2026. The company is well-funded through 2027 and aims to differentiate with selective, long-acting anti-APRIL therapy.
Jade Biosciences to Participate in Two Upcoming Investor Conferences
SAN FRANCISCO and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies ...